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Purpose: To increase our understanding of the mechanisms that remodel the sclera during the development of lens-induced
myopia, when the sclera responds to putative “go” signals of retinal origin, and during recovery from lens-induced myopia,
when the sclera responds to retinally-derived “stop” signals.
Methods: Seven groups of tree shrews were used to examine mRNA levels during minus lens compensation and recovery.
Starting 24 days after eye opening (days of visual experience [VE]) lens compensation animals wore a monocular –5D
lens for 1, 4, or 11 days. Recovery animals wore the –5D lens for 11 days, which was then removed for 1 or 4 days. Normal
animals were examined at 24 and 38 days of VE. All groups contained 8 animals. Scleral mRNA levels were examined
in the treated and contralateral control eyes with quantitative real-time polymerase chain reaction (qPCR) for 27 genes
divided into four categories: 1) signaling molecules, 2) matricellular proteins, 3) metalloproteinases (MPs) and tissue
inhibitors of metalloproteinases (TIMPs), and 4) cell adhesion and other proteins. Four groups (n=5 per group) were used
to examine protein levels. One group wore a –5D lens for 4 days. A second group recovered for 4 days after 11 days of
−5D lens treatment. Two groups were used to examine age-matched normal protein levels at 28 and 39 days of VE. The
levels of six scleral proteins that showed differential mRNA expression were examined with quantitative western blots.
Results: Nineteen of the genes showed differential (treated eye versus control eye) expression of mRNA levels in at least
one group of animals. Which genes showed differential expression differed after 1 and 4 days of compensation and after
1 or 4 days of recovery. The mRNA level for one gene, a disintegrin and metalloproteinase with thrombospondin motifs
1 (ADAMTS1), was upregulated in the treated eyes after 1 day of compensation. After 4 days, transforming growth factor
beta receptor 3 (TGFBR3), transforming growth factor-beta-induced protein ig-h3 (TGFBI), and matrix metalloproteinase
14 (MMP14) mRNA levels were upregulated. Downregulated were mRNA levels for transforming growth factor beta-1
(TGFB1),  transforming  growth  factor  beta-2  (TGFB2),  thrombospondin  1  (THBS1),  tenascin  (TNC),  osteonectin
(SPARC), osteopontin (SPP1), tissue inhibitor of metalloproteinases 3 (TIMP3), and a disintegrin and metalloproteinase
with thrombospondin motifs 5 (ADAMTS5). After 11 days of lens wear, there was no differential expression. During
recovery, after 1 day, treated-eye mRNA downregulation was found for TGFB2, TGFBR1, TGFBR2, TGFBR3, SPARC,
ADAMTS1, ADAMTS5, syndecan 4 (SDC4), and collagen type VI, alpha 1 (COL6A1). After 4 days, TGFB1, TGFB2,
TGFB3, THBS2, and TIMP3 mRNA levels were upregulated in the recovering eye. Significant downregulation, relative
to normal eyes, was found in both the control and treated eyes for most genes after 1 day of compensation; a similar
decrease was found, compared to lens-compensated eyes, after one day of recovery. Protein levels for THBS1 showed
positive correlation with the differential mRNA levels and TGFBR3 showed a negative correlation. No differential protein
expression was found for TGFB2, TGFBI, MMP14, and TIMP3.
Conclusions: The different patterns of differential mRNA expression during minus lens compensation (hyperopia) and
recovery (myopia) show that scleral fibroblasts distinguish between “go” and “stop” conditions. There is evidence of
binocular  global  downregulation  of  genes  at  the  start  of  both  lens  wear  and  recovery.  As  additional  information
accumulates about changes in gene expression that occur during compensation and recovery the “signature” of differential
changes may help us to understand in more detail how the sclera responds in “go” and “stop” conditions.
Refractive errors occur when there is a mismatch between
the axial length of an eye and its refractive power, which is
produced by the cornea, lens and anterior chamber depth.
When the axial length matches the optical power, without
accommodation, the images of distant objects are focused
sharply on the photoreceptors and the eye is emmetropic.
However, if the eye’s axial length becomes longer than the
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focal plane, the images are focused in front of the retina and
the eye is myopic. Juvenile-onset myopia affects a significant
fraction of the world’s population [1].
As  shown  by  studies  in  animal  models  (fish,  chicks,
monkeys, guinea pigs, tree shrews, and other species) [2-6]
and humans [7], an emmetropization mechanism uses visual
signals during the early postnatal period to guide the axial
elongation rate (primarily the vitreous chamber depth) so that
the retina comes to be located close to the focal plane, typically
producing  eyes  that  are  slightly  hyperopic.  The
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903emmetropization mechanism can be stimulated with minus
powered lenses to produce accelerated axial growth.
A minus-power lens shifts the focal plane posteriorly,
moving  it  behind  the  retina  and  making  the  lens-wearing
emmetropic eye hyperopic. In juvenile tree shrews, small
mammals (~150 g), closely related to primates [8] with a well
characterized  emmetropization  mechanism  [9,10],  this
stimulates  the  emmetropization  mechanism  to  produce  a
compensatory increase in the axial elongation rate above the
normal  baseline  rate  and  leads  to  the  eye  becoming
emmetropic while wearing the lens. Nearly all the increased
elongation is due to an increase in vitreous chamber depth;
there is little change to the cornea or lens [11-14]. Refractive
and axial changes can be detected as soon as 2 days after the
start of monocular −5 diopter (D) lens wear [9]; after 11 days
the  compensation  is  typically  complete  [9]  so  that  the
refractive state, measured with the lens in place, is equal to
that of the untreated control eye or age-matched normal eyes.
When the lens is removed after minus lens compensation,
the eye initially is myopic. Over time, the refractive state of
the eye generally recovers until the refractive power of the eye
is again the same as the control and age-matched normal eyes
[9,11,15].  Axial  length  (vitreous  chamber)  measures  have
shown that the recovery occurs primarily because there is
slowing of the axial elongation rate below normal, while the
eye’s  optical  power  continues  to  mature  [16,17].  When
recovery is complete, the axial length in the recovered eye
matches that of normal and untreated control eyes.
It is generally thought that this visually-guided feedback
loop  begins  with  retinally-generated  “go”  signals  that
eventually produce an increased axial elongation rate during
compensation [18,19]. During recovery, retinally-generated
“stop” signals produce a slowed elongation rate [18,20]. The
axial elongation rate of the eye is primarily determined by the
rate  of  expansion  of  the  scleral  shell,  which  is  a  dense
extracellular matrix (ECM) connective tissue produced by
fibroblast cells [21-23]. In tree shrews, it is comprised largely
of collagen fibrils (approximately 90% of scleral dry weight),
predominantly  fibrillar  type  I  collagen  [24,25].  These  are
arranged  in  layers  (lamellae),  along  with  elastin,
proteoglycans, glycoproteins, hyaluronan, and other proteins.
The mechanical properties of the sclera change during
minus  lens  compensation  and  recovery  [11].  During
compensation for a –5D lens, scleral creep rate, a measure of
viscoelasticity, initially rises with a peak after 4 days of lens
wear and then gradually declines as the eye completes its
compensation. The creep rate changes occur in parallel with
the rise and decline of the axial elongation rate. This change
in the sclera may allow normal intraocular pressure to expand
the globe during compensation, perhaps by increasing the ease
with which the scleral lamellae slip across each other. During
recovery, the creep rate rapidly (< 24 h after lens removal)
returns to normal levels, and in some cases, drops below
normal levels (Siegwart, unpublished data, 2007). Although
it appears that “go” and “stop” signals of retinal origin produce
changes in the biochemical composition of the sclera which,
in turn, control its viscoelasticity, it is unclear which of the
scleral structural components, signaling molecules, enzymes
and  their  inhibitors,  cell  adhesion  molecules,  and  other
substances are changed during scleral remodeling.
Previous studies suggest that the process that occurs in
the all-fibrous tree shrew sclera during lens compensation and
recovery  is  tissue  remodeling  rather  than  modulation  of
growth. During minus lens compensation, there is a reduction
in scleral dry weight (~4%) of the treated eyes due to a net
loss of extracellular matrix (ECM) proteins, hyaluronan, and
other  glycosaminoglycans  (GAGs)  [17].  During  recovery
from induced myopia, there is little rebound of dry weight
[17] or type I collagen levels [25], although mRNA levels for
type I collagen and other genes that changed during myopia
development have generally been found to either reverse in
direction or to return to normal. From these studies a general
picture has emerged of increased turnover and loss of ECM
during  myopia  development  and  a  partial  reversal  during
recovery. Numerous genes are involved in tissue remodeling
and studies in tree shrews have found modulation of scleral
mRNA levels after minus lens wear or form deprivation and,
to a more limited extent, during recovery [16,26-30]. The
regulation of mRNA levels is selective, so that levels for some
substances, but not all, differ in the treated eyes, relative to
control  eyes,  during  either  minus  lens  compensation  or
recovery [16]. There is evidence that the transforming growth
factor beta (TGFβ) signaling pathway plays a major role in
the initiation and control of the remodeling process [31].
Despite previous studies, only a relatively small number
of the potential candidate genes have been examined. In this
study,  27  genes  representing  four  functional  groups  were
selected for examination at the mRNA level by quantitative
real-time  polymerase  chain  reaction  (qPCR)  during  lens
compensation  and  recovery:  1)  signaling  molecules,  2)
matricellular proteins, 3) metalloproteinases [MPs] and tissue
inhibitors of metalloproteinases [TIMPs], and 4) cell adhesion
and other proteins. The 27 genes chosen for this study are
meant to be representative of the tissue remodeling process.
They are either known to be involved in tissue remodeling in
general  or  have  been  specifically  implicated  in  scleral
remodeling. A subset of six candidates whose mRNAs were
found  to  be  differentially  expressed  was  examined  at  the
protein  level  using  quantitative  western  blots.  We
hypothesized that, during compensation, specific molecules
initiate  and  participate  in  ECM  remodeling,  and  during
recovery some of the same molecules produce a reversed
pattern  of  mRNA  expression,  while  other  molecules  are
activated or return to normal. The expression signature of the
changes may help us to understand how the sclera responds
to “go” and “stop” signals received from the retina.
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Experimental  groups:  Juvenile  tree  shrews  (Tupaia  glis
belangeri) were raised by their mothers in our breeding colony
on a 14 h light/10 h dark cycle. All procedures complied with
the ARVO Statement for the Use of Animals in Ophthalmic
and Visual Research and were approved by the Institutional
Animal  Care  and  Use  Committee  of  the  University  of
Alabama at Birmingham. Experimental groups were balanced
to include both males and females, and avoided pups from the
same parents wherever possible. The treated eye was selected
to include both right and left eyes and was approximately
balanced within and across groups.
Gene expression study—Three groups of minus lens
compensation animals (n=8 per group) wore a monocular –
5D (spherical power) lens starting at 24±1 days after natural
eye opening (days of visual experience [VE]), with lens wear
continuing for 1, 4, or 11 days. The untreated fellow eye
served as a control. Two recovery groups (n=8) wore the
monocular –5D lens for 11 days, also starting at 24 days of
VE, typically resulting in full compensation. Lenses were
removed and the now-myopic treated eye was allowed to
recover for either 1 or 4 days. Two ‘age-matched’ normal
groups (n=8) were also used – one with 24 days of VE for
comparison with the 1 and 4 day compensation groups, and
one with 38 days of VE for comparison with the 11 day
compensation, 1 day recovery, and 4 day recovery groups.
Protein expression study—Four groups (n=5 per group)
were used to examine protein levels. One group wore a –5D
lens for 4 days. A second group recovered for 4 days after 11
days of −5D lens treatment. Two groups were used to examine
age-matched normal protein levels at 28 and 39 days of VE.
The levels of six scleral proteins (transforming growth factor
beta-2 [TGFB2], transforming growth factor beta receptor 3
[TGFBR3], transforming growth factor-beta-induced protein
ig-h3 [TGFBI], matrix metalloproteinase 14 [MMP14], and
tissue inhibitor of metalloproteinases 3 [TIMP3]) that showed
differential  mRNA  expression  were  examined  with
quantitative western blots.
Lens wear: To attach the goggle containing the –5D lens
firmly  to  the  head  during  lens  treatment,  animals  were
anesthetized  (17.5  mg  ketamine,  1.2  mg  xylazine;
supplemented  with  0.5−2.0%  isoflurane  as  needed)  and
received a dental acrylic pedestal at 21±1  days  of  VE, fol-
lowing procedures  described by Siegwart  and Norton  [32].
Three days later, the goggle  frame  with a  monocular –5D
lens  (PMMA  contact  lens, 12  mm diameter; Conforma
Contact  Lens,  Norfolk,  VA)  was  clipped  to  the  pedestal,
holding the lens in front of the treated eye. The control eye
had  unrestricted  vision  through  an  open  (no  lens)  goggle
frame. The normal groups did not wear a goggle. The goggle
was removed for approximately 2 min in dim illumination
twice daily (approximately 9:30 AM and 4:30 PM) while the
lens was cleaned. During lens cleaning, the animals were kept
in a darkened nest box to minimize exposure to visual stimuli.
Badly scratched lenses were replaced as needed while the
animal was kept in darkness (<30 min).
Axial and refractive measures: At the time the pedestal was
attached, ocular component dimensions were measured under
anesthesia with A-scan ultrasound as described by Norton and
McBrien [33]. Terminal A-scan measures were omitted out of
concern that protracted anesthesia might interfere with retino-
scleral signaling. At the start and end of the compensation and
recovery periods, non-cycloplegic measures of refractive state
were taken on the animals while they were awake using a
Nidek ARK 700-A infrared autorefractor (Marco Ophthalmic,
Inc., Jacksonville, FL)  [34].  Measures  were taken with the
–5D lens in  place and with  it  removed to measure both
the amount of lens compensation and the amount of  induced
myopia.  Cycloplegic  refractive  measures  were  omitted  to
prevent  any  possible  effect  on  retino-scleral  signaling  by
atropine. Previous studies have found that non-cycloplegic
awake autorefractor measures provide a valid estimate of the
amount of induced myopia in tree shrews. Actual values for
each eye differ from the cycloplegic measures by less than 1
D,  and  the  treated-eye  versus  control-eye  differences  are
nearly  identical  between  non-cycloplegic  and  cycloplegic
measures [35].
Tissue  collection:  On  completion  of  the  final  refractive
measures,  animals  were  anesthetized  (17.5  mg  ketamine,
1.2 mg xylazine) and then received a lethal dose of sodium
pentobarbital  (approximately  333  mg/kg)  or  xylazine
(approximately 375 mg/kg). With the animals under deep
anesthesia, both eyes were enucleated and placed into either
RNAlater  solution  (Ambion,  Austin,  TX)  for  the  gene
expression  groups  or  chilled  dissection  buffer  (250  mM
sucrose,  10  mM  Tris,  pH  7.0)  for  the  protein  expression
groups. Extraocular muscles, conjunctiva, and orbital fat were
trimmed from the exterior surface of the eye and the cornea
cut away. After removing the lens and vitreous humor, the
inner and outer scleral surfaces were gently scraped to remove
the  retina,  RPE,  choroid,  and  any  remaining  extraocular
tissue, before freezing the tissue in liquid nitrogen.
Gene expression analysis: Frozen sclera was pulverized to a
fine powder in a chilled Teflon freezer mill (B. Braun Biotech,
Allentown, PA) from which total RNA was isolated using a
RiboPure  kit  (Ambion)  according  to  the  manufacturer’s
instructions, with the addition of an on-filter DNase treatment.
The  purified  RNA  was  quantified  using  a  NanoDrop
spectrophotometer (NanoDrop Technologies, Rockland, ME)
with an average yield per sclera of 6.8±1.9 µg (mean±SD).
RNA quality was confirmed by denaturing gel electrophoresis
(RNA  FlashGel;  Lonza,  Wilmington,  DE).  cDNA  was
synthesized from 1 µg of total RNA in a total reaction volume
of 20 µl using a Superscript III RT kit (Invitrogen, Carlsbad,
CA)  with  minor  modifications  (2.5  µM  anchored  oligo
(dT)20 primers and DTT omitted). The reaction was terminated
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fivefold and stored at –20 °C until use. To minimize potential
variation,  all  8  animals  in  a  given  treatment  group  were
processed (RNA extraction and reverse transcription) at the
same time.
Tree shrew-specific primers for SYBR Green assays were
designed for 27 target genes and the reference gene RNA
polymerase II (POLR2A) using Beacon Designer 7 (Premier
Biosoft International, Palo Alto, CA; Table 1). Initially, for
the  majority  of  candidates,  human-specific  primers  were
developed in regions that showed cross-species homology.
The PCR product generated by these primers from tree shrew
cDNA was then sequenced to allow the design of tree shrew-
specific qPCR primers. For some candidates (apolipoprotein
A-I [APOA1], apolipoprotein E [APOE], syndecan 4 [SDC4],
and transforming growth factor beta receptor 1 [TGFBR1])
tree shrew cDNA sequence was available directly. All primers
were designed to work under the same cycling conditions. All
resulting amplicons were located within the coding region and
most  spanned  at  least  one  intron;  amplicon  identity  was
verified by gel electrophoresis and sequencing.
Relative gene expression was quantified on an iQ5 real
time PCR system using iQ SYBR Green Supermix (Bio-Rad,
Hercules, CA). Reactions were performed in triplicate for all
but 90 of the 1,512 total assays (94%); the remaining were
performed  in  duplicate.  Random  deletion  of  one  of  the
replicates from the triplicate runs did not change the statistical
significance of the results which suggests that the duplicate
reactions are valid measures. For each target gene reactions
were performed in a 15 µl volume containing 300 nM each
primer and the equivalent of 0.5 µl cDNA template. The same
cycling parameters were used for all primer sets: 95 °C ×3 min
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TABLE 1. PRIMERS USED TO EXAMINE GENE EXPRESSION USING QPCR.
  Primer sequence      
Gene Forward Reverse Size Spans
intron
Efficiency
Signaling pathways
TGFB1 ACCAGAAATACAGCAACAATTCC AACCCGTTGATGTCCACTTG 205 Yes 98
TGFB2 GCAGAGTTTAGGGTCTTTCGTTTG CTCGTGAACAGCATCAGTTACATC 189 Yes 104
TGFB3 ATCACCATAACCCGCATCTAATCC CGCACACAGCAGTTCTCCTC 139 Yes 91
TGFBR1 GACCTCCCAACTACTGTAAAGC ATCCTCTTCATTTGGCACTCG 162 Yes 89
TGFBR2 GCTGCCTGTGTGACTTTGG TCCTGGATTCTAGCACTTCTGG 123 Yes 94
TGFBR3 CCCTGGTCTGGCGTCTGAAG GTAACTGCTCCATACTCGTTTCGG 190 Yes 87
FGF2 GGGTCGTGTCTATCAAAGGAG ACATTTAGAAGCCAGCAGTCG 80 Yes 90
FGFR1 CCTGGAGGTCATCATCTACTGC AGAGTTCATGGAAGCACTGGAG 196 Yes 96
APOE GGTGCAGACGCTGTCTGACCA CCTCCAACTCCGCCTTGTAGG 122 Yes 89
APOA1 GCTGTGGTATTGACCTTGGCTGT TTGGCTAAATCCCGCACTCG 110 Yes 100
Matricellular proteins
THBS1 CTGTCAGAACTCAGTCACCATC CCACGGAGACCAGCCATC 136 Yes 81
THBS2 GAGACCGACTTCAGGAACTTC CGAAACCCACTGCGATGC 142 Yes 88
TNC AGACGCCAAGACTCGCTACAG CAGGTTGACACGGTGACAGTTC 184 Yes 88
SPARC GCGAGTTTGAGAAGGTGTGC GCCCGATGTAGTCCAGGTG 126 Yes 78
SPP1 CCGACGACACCGACCATCC GGCTTTGACCTCACTCTGTAAACC 190 No 83
MP/TIMP
MMP3 GCCATCCGAGGAAATGAGG TGTCTCTTCTCGTCAAATCTCC 164 Yes 95
MMP14 CCCTGGAACCTGGCTACCC ATAGGTCTTTCCATTGGGCATCC 104 No 104
ADAMTS1 TGGCAAAAGCAGCACAACCC CACAGGTCTGAGCCCCACAC 100 Yes 92
ADAMTS5 TCTTCCATCCTAACCAGCATTG GGTGGCATCATAAGTCTGTCC 165 Yes 105
TIMP3 CCGTGTCTATGATGGCAAGATG ACAAAGCAAGGCAGGTAATAGC 153 Yes 82
Cell adhesion/other
SDC2 TGATGACGACTACGCTTCTGC CAGGCATCTTGTTCTGTGTCTTC 155 Yes 90
SDC4 CAAGGAACTGGAGGAGAATG GGAAAGTGGCAAAGAGGAG 182 Yes 80
VIM GCTCACCAACGACAAGGC CAGAGTGCTTTCGGCTTCC 121 Yes 94
COL6A1 CGACATCCTGTTCGTGCTGG ATCTGGTTGTGGCTGTACTGC 168 Yes 78
FN1 GCAACTCATCAGCATCCAGCAATATG GGAAACCCAGGAGACCACAAAGC 190 Yes 84
PEDF CCTGAAAGCAACCCAGAACTTGA GACTTGGTAACTTCGCCTTCGTAAC 147 Yes 90
TGFBI CCTCGGCACTCATCTCTCC GCAAATTCTTCATCTTGGCATCG 107 Yes 96
Reference
    POLR2A CTACCAGCCCCAAGTATTC GGTGAGTAAGTAGGAGACG 106 No 101followed by 40 cycles of 95 °C ×15 s, 62 °C ×40 s. Single
gene products were obtained for all reactions as assessed by
melt curve analysis or gel electrophoresis. The ∆∆Ct method
was used [36], first to normalize the expression of the target
gene to the reference gene, and then to compare the relative
expression of the target gene between treated and control eyes,
treated  and  normal  eyes,  control  and  normal  eyes.  The
geometric group mean (for the 8 biological replicates) of these
expression ratios was used to calculate the fold change in gene
expression for each of the target genes. Paired t-tests were
used to assess treated versus control eye differences. Unpaired
t-tests,  assuming  equal  variance,  were  used  to  test  for
differences between all independent groups. The SEM for
unpaired comparisons was calculated using a pooled variance.
For all comparisons p<0.05 was considered significant.
Protein expression analysis: The relative expression levels of
6 proteins, whose mRNA levels were found to change in the
gene  expression  analysis,  were  examined  by  fluorescent
western blotting: TGFB2, TGFBR3, TGFBI, MMP14, and
TIMP3;  glyceraldehyde-3-phosphate  dehydrogenase
(GAPDH) was used as a reference protein. Frozen sclera was
pulverized to a fine powder in a chilled Teflon freezer mill (B.
Braun Biotech, Allentown, PA) and then suspended in 400 µl
RIPA extraction buffer (50 mM tris base, 150 mM NaCl, 1%
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS,
protease inhibitor cocktail [# P8340; Sigma, St. Louis, MO],
pH 8.0). After incubation on ice for 60 min, the homogenate
was centrifuged at 21,000× g for 20 min at 4 °C to pellet
cellular debris; the supernatant was collected and its protein
content quantified (2D quant kit; GE Healthcare, Piscataway,
NJ).
Total scleral protein was suspended in Laemmli sample
buffer, denatured at 95 °C for 5 min and then chilled. Samples
of treated, control, and age-matched normal sclera were run
in triplicate (typically 8 – 14 µg depending on target protein
expression level) on 10% SDS–PAGE resolving gels with a
5% stacking gel, alongside ECL Plex Fluorescent Rainbow
markers (GE Healthcare). Gels were electro-blotted onto low-
fluorescence  PVDF  membranes  according  to  standard
methods. Blots were blocked for 1 h at room temperature with
5% BSA in tris-buffered saline supplemented with Tween-20
(20 mM tris base, 150 mM NaCl, 0.1% Tween-20, pH 7.6;
TBST). The exception was TGFBI which used 5% donkey
serum in TBST due to interaction with the secondary antibody
by BSA. Blots were probed with human specific primary
antibodies  (Table  2),  multiplexed  with  the  anti-GAPDH
antibody, in blocking solution at 4 °C overnight and then
washed 3 times with TBST before being probed with Cy3- or
Cy5-conjugated secondary antibodies in TBST (1 in 2,500
dilution) at room temperature for 1 h. Blots were again washed
3 times with TBST and then dried before imaging at 100 µm
resolution on a Typhoon Trio plus (GE Healthcare) using
settings appropriate for the Cy3 and Cy5 fluorophores.
Blot images were assessed by ImageQuant TL software
(GE Healthcare) to automatically detect protein bands and
subtract  background  noise.  Protein  levels  were  quantified
from the integrated band volume; if multiple protein bands
were detected then the sum of the band volumes was used.
Relative protein levels were calculated by first normalizing
the  target  protein  to  the  GAPDH  reference,  and  then
comparing  between  treated  and  control  eyes,  treated  and
normal eyes, control and normal eyes. The geometric group
mean (for the 5 biological replicates) of these expression ratios
was  used  to  calculate  the  relative  fold  change  in  protein
expression for each of the target proteins. Paired t-tests were
used to assess treated versus control eye differences; unpaired
t-tests  were  used  to  test  for  differences  between  all
independent groups; a p<0.05 was considered significant.
RESULTS
Gene expression study:
Refraction—The refractive changes produced by –5D
lens treatment and recovery are comparable, but not identical,
to those observed in previous studies in which tree shrews
received  similar  visual  treatments  [17,30].  Minus  lens
treatment initially made the treated eyes hyperopic with the
lens in place, relative to the control eyes (Figure 1A) and then
produced a rapid compensation by the treated eye so that the
with-the-lens  hyperopia  decreased  and  the  refraction,
measured without the lens (Figure 1B) became myopic. After
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TABLE 2. HUMAN PRIMARY ANTIBODIES USED IN THE PROTEIN EXPRESSION STUDY.
Protein Concentration Host and type Source
THBS1 0.6 μg/ml Mouse monoclonal Gift of Dr. Murphy-Ullrich (UAB); mAb 133 [37]
TGFBI 0.2 μg/ml Goat polyclonal R&D Systems; AF3925
TGFB2 0.8 μg/ml Rabbit polyclonal Santa Cruz Biotechnology; sc-90
TGFBR3 0.4 μg/ml Rabbit polyclonal Santa Cruz Biotechnology; sc-28975
MMP14 0.2 μg/ml Rabbit polyclonal Santa Cruz Biotechnology; sc-30074
TIMP3 0.4 μg/ml Rabbit polyclonal Santa Cruz Biotechnology; sc-30075
GAPDH 0.4 μg/ml Rabbit polyclonal Santa Cruz Biotechnology; sc-25778
GAPDH 0.4 μg/ml Mouse monoclonal Santa Cruz Biotechnology; sc-47724
         Antibody specificity in tree shrew was validated by antigen blocking or immunoprecipitation followed by mass spectrometry
         (data not shown).11 days of treatment, the treated eyes had fully compensated
for the –5D lens and were myopic with the lens removed.
When lens wear was discontinued, rapid refractive recovery
from the induced myopia occurred, with approximately 50%
recovery after 4 days. The control eyes of the groups generally
showed age-normal refractions. However, there was evidence
of a yoked myopic shift in refraction in both the treated and
control eyes of the group that had 1 day of lens treatment
(Figure 1B). Also, both the treated and control eyes of the
group given 1 day of recovery showed a hyperopic shift in
refraction. Although A-scan ultrasound was not performed at
the end of treatment to avoid any possible effect of anesthesia
on gene expression, previous studies have consistently shown
that refractive changes produced by minus lens treatment and
recovery in tree shrews are due almost entirely to changes in
vitreous chamber depth [16,17].
The expression level of mRNA for the reference gene,
POLR2A, did not vary significantly as a function of age or
treatment  condition.  A  1-way  ANOVA  comparing  the
POLR2A Ct vales of right, left, treated, and control eyes from
all groups did produce a p value of 0.0498. However, Tukey
HSD post hoc tests did not identify a significant difference
between any two groups. Therefore, the expression of the
target genes relative to the expression of POLR2A provides a
valid comparison between the treated and control eyes and
also the eyes of the age-matched normal groups of animals.
Differential effects – general patterns—The pattern of
differential (treated versus control) changes in scleral mRNA
expression levels as a function of time wearing the –5D lens
or recovering from lens-induced myopia is consistent with a
rapid initiation of scleral remodeling in response to minus lens
wear that dissipates as the eyes complete their compensation
for the induced refractive error [16,17]. There is an even more
rapid change at the onset of recovery. The pattern is also
consistent with the previously described modulation of scleral
creep rate that occurs during minus lens compensation and
recovery [11]. This section will describe the overall pattern of
differential  gene  expression.  The  following  section  will
examine  the  specific  genes  and  pathways  that  showed
differential expression.
Figure  1.  Refractive  changes  during
minus lens treatment and recovery. A:
Refractive  differences  (treated  eye  –
control  eye).  Gray  bars  (lens-
compensation  groups)  indicate  the
refractive difference, measured with the
–5D lens in place. Yellow bars indicate
the amount of myopia after 1 and 4 days
of recovery. Normal eyes showed little
difference  between  the  right  and  left
eyes.  B:  Refractive  values,  measured
with  the  –5D  lens  removed,  for  the
treated eyes (filled circles), control eyes
(open circles) and normal eyes (open
triangles). Values are corrected for the 4
D small eye artifact [34]. Note that the
filled and open circles on day 0 (start of
treatment) and day 1 are measurements
from the same group of animals. The
diamond  symbols  at  11  days  of  lens
wear, connected with a solid line, are the
refractions  of  the  treated  and  control
eyes  of  the  1  day  recovery  group
measured at the end of lens wear. These
are plotted to show the yoking of the
control eyes with the treated eyes at the
start  of  lens  wear  and  at  the  start  of
recovery. Error bars indicate standard
error of the mean (SEM).
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908The mRNA levels in the treated eyes, relative to their
fellow untreated control eyes, are summarized in Figure 2 and
the left side of Table 3. At some point during lens treatment
or recovery a significant difference in mRNA expression was
observed in the treated eyes versus the control eyes for 19 of
the 27 genes studied.
To examine the differential effects of monocular minus
lens treatment, it is useful to know what the differential (right
eye versus left eye) mRNA levels are in age-matched normal
eyes (24N in Figure 2). At 24 days of VE, the age when –5D
lens treatment was begun, the average difference between the
mRNA levels in the right and left eyes of normal animals was
very small, and the variability, as measured by the average of
the standard error of the mean values for the right-eye versus
left-eye  expression  levels  of  the  27  genes  was  very  low
(0.17±0.10 fold, mean±SD; Figure 3). Expression for eight
genes was slightly lower in the right eye and expression for
19  was  slightly  higher.  This  pattern  of  up  versus  down
differences was not significantly different from what would
be  expected  from  random  variability  (sign  test,  p>0.05).
Expression for one gene (TGFBR2) was significantly higher
(paired t-test, p<0.05), primarily because the variability of the
mRNA level differences across the eight animals in the group
was extremely low.
After one day of –5D lens wear, three changes were
noted: 1) mRNA expression for one gene (ADAMTS1) was
significantly upregulated in the treated eyes (Figure 2, paired
t-test, p<0.05); 2) the variability in gene expression between
the treated and control eyes was elevated (0.27±0.11 fold;
Figure 3); and 3) as shown by the gray outlines in Figure 2,
the treated eye mRNA expression for 23 of 26 genes was
higher, but not significantly, than expression in the control
eyes. If one were to assume that normally the differential
expression would randomly vary between eyes, with some
expression levels higher in one eye and the rest higher in the
other eye, as in the normal animals at 24 days of VE, the bias
after  one  day  of  treatment  for  the  treated-eye  mRNA
expression levels to be higher than the control-eye values may
be an early sign of differential changes. This upward bias in
the direction of the non-significant changes in expression
level  was  significantly  different  from  random  (sign  test,
p<0.05).
After 4 days of –5D lens wear (Figure 2), when the treated
eyes were rapidly compensating for the lens, 11 genes showed
significant differential expression (p<0.05, paired t-test) as
described  in  the  next  section.  The  direction  of  the  non-
significant differential expression levels was evenly divided;
expression was higher in 8 and lower in 8 genes. Variability
of the differential expression levels was low (0.15±0.06 fold),
as reflected in the smaller SEM values (Figure 3). The mRNA
expression levels from this group were also compared with
normal eyes measured at 24 days of VE as shown on the right
side of Table 3 (“lens wear, 4 days”). The control eye mRNA
levels  were  generally  not  significantly  different  from  the
normal animals, while mRNA levels for five genes were lower
than normal in the treated eyes.
After 11 days of –5D lens wear, when the treated eyes
had compensated for the lens (all were within 1.2 D of full
compensation) there were no significant differences in mRNA
expression between the treated and control eyes (paired t-test,
p>0.05); overall, the pattern was for lower expression in the
treated eyes (lower than control eye for 22 of 27 genes; sign
test,  p<0.05).  Differential  expression  in  this  group  was
characterized by very high variability (0.54±0.44 fold; Figure
3). This was significantly greater variability than found in any
of  the  other  groups  (1-way  ANOVA  across  all  groups,
p<0.00000; Tukey HSD post hoc test, p<0.05, 11 days −5D
versus each other group). The mRNA expression levels from
this group were also compared with normal eyes measured at
38 days of VE as shown on the right side of Table 3 (“lens
wear,  11  days”).  For  the  genes  that  showed  a  significant
difference, the pattern was primarily upregulation for both the
treated and control eyes.
After 1 day of recovery (Figure 2), mRNA expression of
25 genes was lower in the recovering eye compared to the
control eyes. This was significantly different from a random
distribution of up- and downregulation (sign test, p<0.05). For
10 genes the expression was significantly lower (Figure 2,
paired t-test, p<0.05). The variability across animals within
the  group  (0.32±0.16  fold)  was  significantly  higher  in
comparison to that of the group with 4 days of lens wear
(Figure 3), but the variability was smaller than in the group
after  11  days  of  compensation.  Comparing  the  pattern  of
differential expression after one day of lens wear with one day
of recovery (Figure 2), there were more significant differential
changes after one day of recovery than after one day of –5D
lens treatment (filled bars in Figure 2).
After 4 days of recovery, mRNA levels for 5 genes were
significantly upregulated (paired t-test, p<0.05). Levels for 8
other genes were non-significantly higher and 8 were lower,
also  not  significantly.  Variability  of  the  differential  gene
expression levels was relatively low (0.21±0.08 fold, Figure
3) and not significantly different from the variability of the
normal animals measured at 24 days of visual experience.
Differential effects – pathways and specific genes—
The  statistically  significant  differential  changes  in  gene
expression found in this study (filled bars in Figure 2) expand
upon  the  suggestion  from  previous  studies  [16,30]  that
retinally-derived “go” and “stop” signals produce a complex,
selective  remodeling  of  the  scleral  extracellular  matrix.
Differential changes in mRNA levels for signaling proteins,
matricellular  proteins,  MPs,  and  TIMPs,  along  with  cell
adhesion and other proteins were consistent with a pattern,
during  lens  compensation,  of  reduced  ECM  synthesis,
increased  ECM  degradation,  and  reduced  matricellular,
proteoglycan  core  proteins,  and  cell  adhesion  protein
synthesis. The pattern of differential mRNA changes during
recovery suggested a partial reversal of the pattern during lens
Molecular Vision 2011; 17:903-919 <http://www.molvis.org/molvis/v17/a101> © 2011 Molecular Vision
909Figure 2. Summary of differential scleral mRNA expression levels in normal animals, in groups after 1, 4 and 11 days of –5D lens wear and
after 1 and 4 days of recovery from –5D lens wear. Filled bars indicate that mRNA expression was significantly higher or lower in the treated
eye than in the control eye (paired t-test, p<0.05). Unfilled, gray bars indicate differences that did not reach statistical significance. Error bars
indicate standard error of the mean (SEM).
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ycompensation; four genes (TGFB2, TGFBR3, ADAMTS1, and
TIMP3) showed differential mRNA regulation in opposite
directions during minus lens wear and recovery. However,
other mRNAs that did not differentially change during lens
compensation were differentially expressed during recovery
(Figure 2, Table 3).
Differential changes were found in the mRNA levels of
genes in the TGFβ signaling pathway. After 4 days of minus
lens  wear,  two  TGFβ  isoforms  (TGFB1,  TGFB2)  were
downregulated (–1.4 and –2.2 fold) and one TGFβ receptor
(TGFBR3)  was  upregulated  (+1.7  fold).  After  1  day  of
recovery,  TGFB2  and  all  three  TGFβ  receptors  were
downregulated (–1.8, –1.9, –1.6, –3.1 fold). After 4 days of
recovery, mRNA levels for all three TGFβ isoforms were
upregulated (+1.2, +1.6, +1.8 fold) while the mRNA levels
for the three TGFβ receptors were not significantly different.
In general, mRNA levels for TGFβ and its receptors were
regulated in opposite directions. The changes in the TGFβ
signaling pathway are consistent with previous studies [31]
that suggest TGFβ is involved in scleral remodeling during
lens compensation and recovery. The only effect on the FGF
signaling pathway was downregulation of FGF2 mRNA after
1 day of recovery. Neither APOA1, which has been implicated
in chick sclera [20], nor APOE, which often serves a role
similar to APOA1 in mammals [37,38], showed statistically
significant differential changes during lens wear or recovery.
Differential changes were observed in the mRNA levels
of all five matricellular proteins examined. After 4 days of
–5D  lens  wear, THBS1, TNC, SPARC,  and  SPP1  were  all
downregulated (–2.3, –1.6, –1.4, –1.4 fold). After 1 day of
recovery SPARC was downregulated (–1.7 fold) and after 4
days of recovery THBS2 was upregulated (+1.6 fold).
Consistent  with  previous  studies  [16],  there  were
differential effects on MP and TIMP mRNA levels suggesting
increased degradation during lens compensation and a partial
reversal  during  recovery.  mRNA  for  ADAMTS1,  an
aggrecanase, was upregulated (+2.8 fold) after 1 day of minus
lens wear. After 4 days of lens wear, MMP14 mRNA was
upregulated (+2.8 fold) in treated eyes while ADAMTS5 and
TIMP3 mRNA levels were downregulated (–1.3, –2.8 fold).
After 1 day of recovery, mRNA levels for ADAMTS1 and
ADAMTS5 were both downregulated (–4.0, –2.0 fold). After
4 days of recovery TIMP3 mRNA was upregulated (+2.0
fold). ADAMTS1 and TIMP3 were two of four genes that were
differentially  regulated  in  opposite  directions  during  lens
compensation and recovery. Gene expression for MMP3 was
not differentially regulated.
mRNA levels for TGFBI, which has been implicated in
decreasing  the  adhesion  of  fibroblasts  to  collagen  matrix
[39]  was  upregulated  at  4  days  of  lens  wear  (+1.9  fold).
SDC4 and COL6A1 mRNA levels were downregulated after
1 day of recovery (–1.4, –1.8 fold).
Binocular  changes—In  addition  to  examining
differential expression levels between the treated and control
eyes, we also compared the mRNA expression levels in the
treated and control eyes with expression levels in normal
animals.  The  top  panel  of  Figure  4A  repeats  the  1  day
differential results from Figure 2. The middle and bottom
panels and the right side of Table 3 (“lens wear, 1day”) show
the mRNA levels in the group with 1 day of –5D lens wear
compared with the normal group with 24 days of VE. In this
Figure 3. The average of the SEM values
of the differential gene expression for all
27 genes is shown for the 24 VE normal
group (day 0) and for each of the lens-
wear  and  recovery  groups.  The  error
bars  indicate  the  variability  (standard
deviation) of the SEM values for each
group.
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912comparison, we assumed that the mRNA expression values
for the normal group (average of right and left eyes) were the
baseline against which the 1day of lens wear group should be
compared. The changes from the normal animals indicate the
initial  response  of  both  the  control  and  treated  eyes  to
monocular hyperopia. The middle panel shows the difference
in mRNA expression between the treated eyes versus normal
eyes; the bottom panel shows the control eye versus normal
eye difference.  The dominant  early  response  to hyperopia
(–5D lens) was downregulation in both the treated and  con-
trol eyes (sign test p<0.05). Nineteen of the 27 genes showed
significant downregulation (unpaired t-test, p<0.05). In both
eyes, mRNA expression levels for 13 genes were significantly
lower. In addition, expression levels for another 6 genes were
significantly lower in the control eyes compared to normal.
This yoked response contrasted with the differential effects
(top panel), where a significant difference was found in the
mRNA  levels  for  only  one  gene  (ADAMTS1),  and  the
direction was upregulation of the treated eyes. The overall
pattern of the treated eye versus control eye differences was
upregulation of mRNA levels (top panel of Figure 4A), but,
relative  to  normal,  the  response  in  the  treated  eyes  was
downregulation. The differential trend toward upregulation
occurred  because  the  mRNA  of  the  control  eyes  was
downregulated, relative to normal, by a larger amount than
was the case for the treated eyes.
We also compared the mRNA expression levels of the
control  and  treated  eyes  of  the  animals  with  one  day  of
recovery  with  two  groups.  One  comparison  was  with  the
group with that wore the lens for 11 days and had compensated
for the –5D lens (Figure 4B). In this comparison, we assumed
that the mRNA expression values for the treated and control
eyes of the 11 day lens-wear group were the baseline against
which the 1 day of recovery group should be compared; both
groups  wore  the  lens  for  the  same  time  period  and
compensated similarly (Figure 1B), but the 1 day recovery
Figure 4. Summary of the early scleral mRNA responses. A: Differences after one day of lens wear. Top row: Fold difference between the
treated and control eyes after 1 day of –5D lens wear, as shown in Figure 2. Middle row: Treated eye scleral mRNA levels relative to those
of eyes in the 24 VE normal group. Bottom panel: Control eye scleral mRNA levels relative to those of eyes in the 24 VE normal group. B:
Differences after one day of recovery. Top row: Fold difference between the treated and control eyes after 1 day of recovery, as shown in
Figure 2. Middle row: Treated eye scleral mRNA levels relative to treated eyes in the group with 11 days of –5D lens treatment. Bottom panel:
Control eye scleral mRNA levels relative to those of control eyes in the group with11 days of –5D lens treatment. Filled bars indicate that the
difference was statistically significant. Paired t-test, p<0.05, for treated control eye comparisons (top panels); unpaired t-test for other
comparisons (middle and bottom panels). Unfilled, gray bars indicate differences that did not reach statistical significance. Error bars indicate
standard error of the mean (SEM).
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913group was measured a day later, after 24 h with the lens
removed. The changes of both the control and treated eyes
from this group indicate the initial response to monocular
myopia. Interestingly, the dominant early response to myopia
(recovery), like the response to hyperopia (Figure 4A), was
mRNA downregulation in both the treated and control eyes
(sign test p<0.05). The differential downregulation at 1 day of
recovery  (top  panel  in  Figure  4B)  was  due  to  a  larger
downregulation in the treated eyes than in the control eyes.
The other comparison of the recovery groups was with
the normal animals at 38 days of VE. The pattern for the
animals with 1 day of recovery was similar to that described
above, a general downregulation of the treated eyes and, to
some extent, the control eyes. The group with four days of
recovery showed numerous significant differences (p<0.05,
unpaired t-test) between the treated and control eye mRNA
levels  and  normal  levels,  including  both  up-  and
downregulation in the treated and control eyes compared to
normal values.
Overall parallel patterns of mRNA levels—In addition
to the initial yoked downregulation of mRNA levels in the
treated and control eyes, there is an overall parallel pattern of
the control and treated eyes across all of the lens wear and
recovery groups. Figure 5 shows the mRNA expression levels
in the treated and control eyes at each time point of –5D lens
wear and recovery relative to the initial values measured at 24
days of VE. It also compares the older (38 days of VE) normal
group with the 24 day normal group, and shows that there was
a small downward trend in mRNA levels as a function of age.
Superimposed on this is a pattern that is similar for most of
the genes and for the treated and the control eyes in the treated
groups. The relative downregulation in the treated and control
eyes at 1 day of –5D lens and again after 1 day of recovery,
described in Figure 4, can clearly be seen here. Beyond that,
however, the treated and control eye mRNA levels trended in
the same direction, up toward the original normal levels after
4 and 11 days of lens wear and, for both eyes, back toward the
original normal levels after 4 days of recovery. Thus, there
appeared to be an overall pattern of yoking of the treated and
control eyes throughout lens compensation and recovery.
Protein expression study:
Refraction—The refractive changes produced by –5D
lens treatment and recovery in the western blot animals (data
not shown) were comparable to the PCR animals and previous
studies [17,30].
Western  blotting—Six  proteins  (TGFB2,  TGFBR3,
THBS1,  TGFBI,  MMP14,  and  TIMP3)  that  showed
differential mRNA expression after 4 days of –5D lens wear
were examined by western blotting. GAPDH was measured
as the reference protein. After 4 days of –5D lens wear, the
abundance  of  two  proteins  was  significantly  lower  in  the
treated eyes relative to the control eyes: TGFBR3 (–1.2 fold)
and THBS1 (–4.9 fold). After 4 days of recovery, none of the
proteins  examined  showed  a  significant  difference  in
abundance between the treated and the control eyes. There
were no significant differences between right and left eye
protein levels or between levels in the young (24 days of VE)
versus older animals (39 days of VE).
Comparison with mRNA results—Overall, there was
not good agreement between the mRNA and protein data.
Table 4 compares the differential mRNA expression patterns
with  the  differential  protein  results  for  the  two  treatment
conditions  examined  (4  days  of  lens  wear  and  4  days  of
recovery). The treated versus control eye fold difference for
the proteins is shown followed by NS if the difference did not
reach statistical significance (p>0.05, paired t-test). In two
cases, (THBS1 and TGFBR3 after 4 days of lens wear) both
the differential mRNA expression and the differential protein
expression  reached  statistical  significance.  In  one  case
(THBS1) both increased. In the other (TGFBR3) the treated
eye mRNA levels were upregulated while the protein levels
were downregulated. There were three additional instances
where the protein levels changed in the same direction as the
mRNA levels (indicated with bolding of the type), but the
differential  protein  expression  did  not  reach  statistical
significance.
Figure 5. Expression of all genes in the treated and control eyes
normalized to the levels of the normal animals measured at 24 days
of VE. The filled circles at 3 days of recovery are the 38 VE normal
mRNA values normalized to the 24 day normal values.
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The results of this study add to our understanding of the scleral
changes  that  occur  during  minus  lens  compensation  and
recovery by revealing the patterns of gene expression both
across  a  large  number  of  candidate  genes,  and  also  as  a
function of time. Distinctive mRNA expression patterns were
found:  both  differential  patterns  and  yoked,  directional
patterns that changed over time for genes in four categories 1)
signaling pathways, 2) matricellular proteins, 3) MPs and
TIMPs, 4) cell adhesion and other proteins. These patterns
suggest  that  genes  within  each  group  may  participate  at
differing times to produce remodeling of the sclera that results
in accelerated axial elongation in response to hyperopia and
reduced axial elongation in response to myopia.
Differential patterns: Differential patterns, in which the
treated eyes change from the control eyes, are of interest
because it is the treated eyes that increase their creep rate and
axial elongation rate during lens compensation and decrease
them  during  recovery,  whereas  the  control  eyes  remain
relatively, but not completely, normal [11].
Signaling pathways—The changes in the mRNA levels
of the TGFβ isoforms (decreased at 4 days of lens wear,
increased at 4 days of recovery) confirm and extend findings
from previous studies using form deprivation that suggested
the involvement of the TGFβ signaling pathway [31]. A novel
finding of this study is the modulation of mRNA levels for all
three TGFβ receptors. This suggests that receptor expression,
in  addition  to  expression  of  the  TGFβ  isoforms,  may  be
involved in TGFβ signaling in tree shrew sclera during lens
compensation  and  recovery.  Of  particular  interest  is  the
increased mRNA expression after 4 days of lens wear, and
decreased expression after 1 day of recovery, of the non-
signaling  receptor  TGBFR3,  also  known  as  betaglycan.
Betaglycan regulates TGFβ access to the signaling receptors.
When anchored in the cell membrane, betaglycan facilitates
signaling by presenting TGFβ to the signaling TGFβ receptors
[40]. In contrast, soluble betaglycan is a potent inhibitor that
sequesters TGFβ in the extracellular space preventing it from
binding to the signaling receptors [41]. Soluble betaglycan is
produced from the membrane-anchored form by proteolytic
cleavage, a process that is thought to be mediated by MMP14
[42].  The  relative  increase  in  mRNA  at  4  days  for  both
betaglycan and MMP14 is consistent with the idea that there
may  be  increased  production  of  the  inhibitory,  soluble
betaglycan. If there were more soluble betaglycan and less
TGFβ, as suggested by the decrease in TGFβ mRNA, there
could be an overall reduction in TGFβ signaling during lens
compensation.  During  recovery  there  was  an  increase  in
TGFβ  mRNA,  a  decrease  in  betaglycan  mRNA,  and
MMP14 mRNA returned to normal levels in the treated eyes,
which might combine to increase TGFβ pathway signaling.
In chicks, apolipoprotein–A1 has been suggested to be a
“stop” signal in retina and sclera [20]. However, mRNA levels
for APOA1 and apolipoprotein-E, which in mammals plays a
similar  role  to  APOA1  [37.38],  did  not  show  differential
changes  during  lens  compensation  or  recovery.  However,
mRNA levels for a gene from the fibroblast growth factor
signaling pathway, FGF2, were downregulated after 4 days
of recovery.
Matricellular proteins—Matricellular proteins are non-
enzymatic,  non-structural  proteins  that  are  thought  to
modulate  interactions  between  various  ECM  components
[43]. This study found differential changes in the mRNA
levels  of  all  of  the  candidate  genes
(SPARC, THBS1, THBS2, TNC, SPP1)   suggesting   general
involvement  of  the  matricellular  proteins  in  scleral  tissue
remodeling  during  lens  compensation  and  recovery.  The
significant differential downregulation of 4 of the 5 after 4
days of –5D lens wear when the increase in scleral creep rate
and increase in axial elongation rate are at a maximum [11]
suggests  that  a  reduction  in  matricellular  protein-related
activity may play a role in increasing scleral creep rate.
TABLE 4. DIFFERENTIAL MRNA AND PROTEIN COMPARISON.
Gene 4 Days –5D Lens 4 Days Recovery
TGFB2 mRNA −2.2 1.6
protein −1.3 NS −1.3 NS
TGFBR3 mRNA 1.7 −1.5 NS
protein −1.2 1.0 NS
THBS1 mRNA −2.3 1.8 NS
protein −4.9 3.2 NS
TGFB1 mRNA 1.9 −1.1 NS
protein 1.0 NS −1.2 NS
MMP14 mRNA 2.3 1.2 NS
protein 1.0 NS 1.0 NS
TIMP3 mRNA −2.8 2.0
protein 1.0 NS −1.1 NS
                Values are fold changes. Bold indicates changes in the same direction.
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915MPs and TIMPs—The findings of this study support
previous studies that suggest the involvement of MPs and
TIMPs in scleral tissue remodeling [16,44-46]. The levels of
MMP14, a membrane bound MMP that activates proMMP-2,
directly cleaves collagen and proteoglycan core proteins, and
produces soluble betaglycan, were higher in the treated eye
sclera after 4 days of –5D lens treatment while the levels of
TIMP3, an inhibitor of MMP14, were lower. Together, these
changes in gene expression could potentially increase the
activity  of  MMP14  which  in  turn  may  contribute  to  the
increase in scleral creep rate by degrading collagen fibrils at
the edges of the scleral lamellae, increasing the ease with
which the lamellae slip across each other.
Two metalloproteinases, not previously studied in tree
shrew,  ADAMTS1  and  ADAMTS5,  also  known  as
aggrecanase  3  and  aggrecanase  2,  respectively,  were
considered good candidates for examination because of their
potential to cleave the core protein of the large proteoglycan
aggrecan. Previous studies have shown that the fibrous sclera,
surprisingly, contains relatively large amounts of this cartilage
proteoglycan,  and  that  scleral  aggrecan  mRNA  levels  are
decreased  during  lens  compensation  and  increased  during
recovery  in  tree  shrews  [30,47].  The  modulation  of
ADAMTS1 appeared as an early, transient response to both
hyperopia and myopia. After 1 day of –5D lens treatment the
mRNA levels for ADAMTS1 were nearly threefold higher in
the treated eye sclera than in the control eye sclera and after
1  day  of  recovery  they  were  fourfold  lower.  Both  initial
changes were largely gone at 4 days of lens treatment and 4
days of recovery. These data suggest that an increase (lens
wear) and decrease (recovery) in aggrecan cleavage coupled
with  a  decrease  (lens  wear)  and  increase  (recovery)  of
aggrecan mRNA, might be early steps in the tissue remodeling
processes that quickly changes aggrecan levels. Changes in
aggrecan  content,  which,  due  to  its  large  size  is  located
between  the  scleral  lamella  [30],  may  contribute  to  the
changes in GAG content [17], and the modulation of scleral
creep rate during lens compensation and recovery.
Cell adhesion and other proteins—Only three of the
seven  candidate  genes  examined  in  this  category  showed
differential  changes.  mRNA  for  TGFBI,  which  has  been
implicated  in  decreasing  the  adhesion  of  fibroblasts  to
collagen matrix [39], was increased at 4 days of lens wear
while mRNA for SDC4 and COL6A1 were reduced after 4
days of recovery. mRNA for vimentin (VIM), an intermediate
filament protein involved in cytoskeletal changes, that has
been found to upregulate in response to form deprivation in
chick retina [20], did not show differential changes at any
point in lens compensation or recovery.
Global patterns of differential changes: In addition to the
individual  differential  changes  that  reached  statistical
significance, general patterns of differential changes emerged
that  appeared  to  reflect  overall  scleral  responses  to  lens
compensation  and  recovery.  As  noted  in  Figure  2,  the
difference in mRNA expression, across all genes, between the
right and left eyes of normal animals was very small, and the
variability was very low. This pattern was significantly altered
throughout  the  11  days  of  –5D  lens  wear  and  4  days  of
recovery. Thus, larger differences and/or higher variability
provide a sense of the dynamics of scleral gene expression and
appear to be general indicators that the scleral fibroblasts were
responding  to  the  retinally-derived  signals  produced  by
hyperopia and myopia.
There  was  an  overall  trend  toward  higher  expression
levels in the treated eyes relative to control eyes (Figure 2)
after  1  day  of  lens  wear  that  transitioned  to  selective
bidirectional modulation after 4 days that suggests that there
is selective regulation of the mRNA levels during the most
rapid axial elongation phase with the highest scleral creep rate.
After 11 days of lens treatment, when most eyes had fully
compensated for the lens and (as shown in prior studies [11])
axial elongation rate had slowed, there were no significant
mRNA differences. However, the variability between treated
and control eye mRNA levels was very high, suggesting the
scleras had not returned to a normal state. This is consistent
with the fact that the sclera is in an elongated state, relative to
normal, and that the scleral creep rate is still above normal
levels [48].
The high variability in mRNA levels present after 11 days
of lens compensation (Figure 3) rapidly transitioned, after 1
day of recovery, to overall lower variability and significantly
lower mRNA levels in the treated eyes versus the control eyes
(Figure  2).  This  suggests  that  there  is  a  rapid,  strong
differential response to the initial myopia that is opposite in
direction to the overall upward differential response to the
initial hyperopia. The rapid (1 day) emergence of significantly
downregulated  mRNA  levels  in  the  recovering  eyes,  in
contrast to the slower emergence of significant differential
mRNA levels at the onset of lens wear (compare 1 day lens
wear versus 1 day recovery in Figure 2) may suggest a stronger
response to myopia than to hyperopia, or may reflect the fact
that the sclera, after 11 days of lens compensation, is not
normal and may to be able to respond quickly to the initial
myopia at the onset of recovery. Indeed, measures of scleral
creep rate after 1 day of recovery have found that scleral creep
rate drops rapidly (Siegwart, unpublished data, 2007). This
rapid transition may also provide insight into the difference
between the response of the eyes during recovery (when their
elongation and creep rates drop below normal) versus the
response of normal age-matched animals that begin to wear
plus lenses and show little change in the axial elongation rate
in response to a similar amount of myopia [10]. After 4 days
of recovery, the pattern of mRNA differential expression had
transitioned to a bidirectional pattern that was similar to the
transition from 1 to 4 days of –5D lens treatment.
Global binocular changes: As shown in Figure. 4, Figure
5, and in Table 3, the dominant early scleral mRNA response
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wear) and myopia (1 day of recovery) was lower mRNA levels
in  both  the  treated  and  control  eyes.  Two  aspects  of  this
finding are of interest.
First, the untreated control eye scleras responded, and
followed the same initial pattern as the treated eye scleras. It
is not clear how a monocular treatment produces changes in
the control eyes, but control-eye yoking and anti-yoking has
been reported in several different species [11,16,49-52]. It is
possible,  but  seems  unlikely,  that  wearing  the  –5D  lens
produced  changes  in  the  behavior  of  the  animals  (head
position, pupillary constriction, etc.) that altered the visual
experience  of  the  control  eyes.  It  seems  more  likely  that
activity  levels  in  centrally-mediated  binocular  efferent
pathways are altered. For instance, in monocularly treated
chicks, there is a binocular decrease in choroidal blood flow
that is greater in the treated eye, but nonetheless produces a
substantial reduction in choroidal blood flow in the control
eyes [53]. Such a change, if it occurred in tree shrews, could
affect the global metabolism of the control eyes.
Second, the treated-eye scleras initially responded the
same way to both hyperopia and myopia. This finding raises
the possibility that the initial scleral response to hyperopia and
myopia  is  similar,  possibly  a  general  tissue  remodeling
response, that is then fine-tuned to produce the changes that
lead to opposite changes in scleral creep rate.
The yoked downregulation in both the treated and control
eyes, which is not apparent in the differential data that showed
a trend toward higher levels in the treated eyes after 1 day of
–5D lens and lower levels after 1 day of recovery, clouds the
issue of how one should interpret a difference between the
treated and control eye. What does it mean, functionally, if
there is differential upregulation in the treated eye but the
actual overall mRNA levels in that treated eye are decreased
from  normal?  Generally,  a  treated  versus  control  eye
difference is interpreted as a change in the treated eye because
the untreated control eye is considered to be relatively normal.
The data from this study suggest that this assumption may be
insufficient if the point is to determine how gene expression
actually changed in the treated eye and produced changes in
the  scleral  biochemistry.  Presumably,  both  the  difference
between the treated and control eyes and the actual change in
the treated and control eye scleras are important. Possibly, it
is the relative levels of expression of different genes and their
subsequent  interaction  that  has  functional  consequences
rather than the absolute level of expression of a particular
gene.
The  pattern  of  directional  changes  during  lens
compensation and recovery where the mRNA levels of most
of the genes moved in the same direction from one time point
to the next in both the treated and control eyes (Figure 5)
suggests there may be a global mechanism that affects the
expression  of  many  genes  simultaneously  during  lens
compensation and recovery. On this background of global
directional  change  there  appear  to  be  superimposed  more
specific individual changes that create treated versus control
eye differences. How global directional changes might be
induced is unclear, particularly since they also occur in the
untreated control-eye sclera.
Protein levels versus mRNA levels: Overall, there was
poor agreement between the mRNA and protein data, which
is not surprising given that many studies have shown poor
correlation between mRNA and protein levels under a variety
of conditions [54]. Both are snapshots that do not capture the
dynamic properties of either transcription or translation into
protein. Without knowledge of the specific reason for a lack
of correlation between steady-state mRNA and protein levels,
a  change  in  steady  mRNA  level  without  a  corresponding
change  in  the  steady-state  level  of  the  protein  cannot  be
dismissed as functionally unimportant. In particular, it should
be kept in mind that a change in steady-state mRNA levels,
regardless of the consequences of the change, may indicate a
response  by  the  cell  to  an  external  signal  which  may  be
important in understanding the signaling pathways involved.
Conclusions: The results of this study suggest that the
regulation  of  scleral  gene  expression  during  lens
compensation  and  recovery  is  in  some  respects
straightforward, and in other respects very complex. It is clear
that the visually-guided emmetropization mechanism rapidly
regulates  scleral  gene  expression  in  a  highly  controlled
fashion. Genes in a variety of pathways are involved and there
is evidence that there may be underlying global shifting of
gene expression that needs to be taken into account. The
yoking of treated and control eye gene expression and the
subsequent  question  of  the  functional  meaning  of  treated
versus  control  eye  differences  adds  complexity  to  any
interpretation of the changes in gene expression. It does not
appear that the regulation of a few key genes in the treated eye
sclera will be sufficient to explain the tissue remodeling and
changes in the mechanical properties of the sclera. This is not
particularly surprising given that tissue remodeling, which has
been studied for many years in other tissues, is known to be
complex, and there is no particular reason to assume that it
would be any less complicated in the sclera.
The  results  of  this  study,  like  most  previous  studies,
suggest that the magnitude of scleral gene expression changes
during  lens  compensation  and  recovery  are  small.  A
potentially important point to be taken from the directional
changes, that were highly significant by sign test while many
of  the  individual  gene  expression  changes  were  not
statistically significant, is that numerous small changes in
gene  expression  may  combine  to  produce  a  larger  effect.
While many of these small changes may not, individually,
reach statistical significance because of small sample size,
their combined effect may be the tissue remodeling process
that we are attempting to explain. The changes observed in
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may require an understanding of patterns of gene expression,
not just individual significant differences between the treated
and control eye.
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